BOUVIER P.; MOURLEVAT F.; PICHAT L.; SERVIN A.; VIEL C., J. LABELLED COMPOUNDS AND RADIOPHARM., 24,(1987) N 4, 448-453
作者:BOUVIER P.、 MOURLEVAT F.、 PICHAT L.、 SERVIN A.、 VIEL C.
DOI:——
日期:——
[EN] PLPRO INHIBITORS<br/>[FR] INHIBITEURS DE PLPRO
申请人:[en]HUAHAI US INC.
公开号:WO2023114379A1
公开(公告)日:2023-06-22
Provided herein are novel compounds (e.g., Formula X or Y), pharmaceutical compositions, and methods of using the same. The compounds herein can typically inhibit PLpro activities. The compounds herein can also be used for treating a variety of diseases or disorders, such as viral infection caused by a coronavirus such as SARS-CoV- 2.
Syntheses of stable-isotope labeled [M+7] and [M+6] 2-(methylamino)imidazole
作者:Yinsheng Zhang
DOI:10.1002/jlcr.625
日期:2002.10.30
Stable isotope-labeled 2-methylaminoimidazole (M+7 and M+6) was required as an intermediate in the synthesis of mass labeled drug candidates. These two isotopomers were synthesized with total yields of 24 and 36%, respectively. Labeled 2-aminoimidazole (M+4) was prepared from labeled isothiourea (M+3) and 2-aminoacetaldehyde dimethyl acetal (M+1 and M+2). The (M+1) version of 2-aminoacetaldehyde dimethyl